title: Decreased serum lipocalin-2 levels in human immunodeficiency virus-infected patients: increase during highly active anti-retroviral therapy.
abstract: Although neutrophil gelatinase-associated lipocalin (NGAL) may play a pivotal role in the innate immune response, there are currently no data on NGAL levels in human immunodeficiency virus (HIV)-infected patients. In this study we aimed to examine the regulation of NGAL in HIV infection. The regulation of NGAL in HIV infection was examined by different experimental approaches, including studies in peripheral blood and mononuclear cells (MNC) from bone marrow aspirates before and during highly active anti-retroviral therapy (HAART). We found that: before initiating HAART, HIV-infected patients (n = 37) had significantly decreased serum NGAL levels compared with healthy controls (n = 26); (ii) during HAART, there was a gradual and significant increase in NGAL concentrations reaching levels comparable to those in healthy controls after 12 months; (iii) this increase was seen primarily in virological responders to HAART (HIV RNA level <200 copies/ml after 24 months); (iv) phytohaemagglutinin-stimulated NGAL release in MNC cells from bone marrow aspirates was decreased in untreated HIV-infected patients compared with healthy controls, but increased after 26 weeks on HAART; and (v) there was a significant positive correlation between neutrophil counts and NGAL levels at all time-points during HAART. We have shown decreased NGAL levels in HIV-infected patients, potentially reflecting decreased number and function of neutrophils as well as impaired bone marrow myelopoiesis. These abnormalities were reversed by successful HAART. Our findings underscore further the involvement of neutrophils and innate immunity in HIV-related immunodeficiency.
authors.affiliation: Research Institute for Internal Medicine, Rikshospitalet-Radiumhospitalet Medical Center, Unviersity of Oslo, Oslo, Norway. linn.landro@medisin.uio.no
authors.forename: L
authors.initials: L
authors.lastname: Landrø
authors.forename: J K
authors.initials: JK
authors.lastname: Damås
authors.forename: T H
authors.initials: TH
authors.lastname: Flo
authors.forename: L
authors.initials: L
authors.lastname: Heggelund
authors.forename: T
authors.initials: T
authors.lastname: Ueland
authors.forename: G E
authors.initials: GE
authors.lastname: Tjønnfjord
authors.forename: T
authors.initials: T
authors.lastname: Espevik
authors.forename: P
authors.initials: P
authors.lastname: Aukrust
authors.forename: S S
authors.initials: SS
authors.lastname: Frøland
mesh_terms: D000209:Acute-Phase Proteins; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D001854:Bone Marrow Cells / Q000378:metabolism; D018791:CD4 Lymphocyte Count; D002478:Cells, Cultured; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D000071068:Lipocalin-2; D054834:Lipocalins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000097:blood*; D012367:RNA, Viral / Q000097:blood; D019562:Viral Load
chemical_list: D000209:Acute-Phase Proteins; D019380:Anti-HIV Agents; C489506:LCN2 protein, human; D000071068:Lipocalin-2; D054834:Lipocalins; D011518:Proto-Oncogene Proteins; D012367:RNA, Viral